Monoclonal antibodies Boehringer Ingelheim and Invetx

Boehringer Ingelheim and Invetx announce strategic collaboration to advance monoclonal antibody biotherapeutics in animal healthBoehringer Ingelheim and Invetx announce collaboration to discover, develop and commercialize novel veterinary medicinesStrengthening partnership efforts to accelerate innovation and growth is one of the key elements of Boehringer Ingelheim ’s strategy
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news